Monte Rosa Therapeutics (GLUE) Research & Development (2020 - 2026)

Monte Rosa Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $44.1 million for Q1 2026.

• In Q1 2026, Research & Development rose 36.9% year-over-year to $44.1 million; the TTM figure through Mar 2026 stood at $153.4 million (up 21.03% YoY), while the FY2025 annual figure was $141.5 million, up 16.4% from the prior year.
• Research & Development was $44.1 million for Q1 2026 at Monte Rosa Therapeutics, up from $42.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $44.1 million in Q1 2026 to a low of $17.9 million in Q1 2022.
• Historically, Research & Development has averaged $29.6 million across 5 years, with a median of $28.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 93.2% in 2022, then dropped 3.51% in 2024.
• A 5-year view of Research & Development shows it stood at $24.9 million in 2022, then climbed by 9.12% to $27.1 million in 2023, then soared by 43.23% to $38.9 million in 2024, then gained by 8.01% to $42.0 million in 2025, then advanced by 4.98% to $44.1 million in 2026.
• The last three Research & Development figures came in at $44.1 million (Q1 2026), $42.0 million (Q4 2025), and $36.7 million (Q3 2025), per Business Quant data.